2014 Fiscal Year Final Research Report
The development of new molecular target treatment drug for neuroblastoma using MYCN transgenic mouse
| Project/Area Number |
24592698
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KINOSHITA Yoshiaki 九州大学, 大学病院, 准教授 (80345529)
TAGUCHI Tomoaki 九州大学, 医学研究院, 教授 (20197247)
KOHASHI Kenichi 九州大学, 医学研究院, 教授 (10529879)
MIYOSHI Kina 九州大学, 大学病院, 医員 (20621709)
TAJIRI Tatsuro 京都府立医科大学, 医学(系)研究科(研究院), 教授 (80304806)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 神経芽腫 / hedgehog signal |
|---|
| Outline of Final Research Achievements |
We used the MYCN transgenic mouse which was a neuroblastoma model mouse for determining the possibility of the new molecular target in the neuroblastoma. The tumor samples were obtained from homo and hetero MYCN transgenic mouse. The pathological examination was performed for homo and hetero MYCN transgenic mouse samples. And Hh signal proteins (Sonic Hh, GLi1, Patched) were dertermined using immunostaining method. H.E. stains of both samples were shown undifferentiated subtype of neuroblastoma and there were not differences between both groups. Sonic Hh, Patched was strong positive, but the GLi1 was negative in both group. From the results, there was not difference between two groups, even if the survival rate of each group were different. In the human neuroblastoma specimen, the GLi1 was strongly positive. However, in MYCN transgenic mouse, GLi1 was negative. Therefore the Hh signal activation was different between human neuroblastoma and MYCN trancegenic mouse.
|
| Free Research Field |
小児外科学分野
|
